Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name FGFR2 N549K
Gene Variant Detail

FGFR2 N549K (gain of function)

Relevant Treatment Approaches FGFR Inhibitor (Pan) FGFR2 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 - WAC FGFR2 M537I FGFR2 M538L FGFR2 N549H FGFR2 N549K FGFR2 N549T FGFR2 L550F FGFR2 V564F FGFR2 V564I FGFR2 E565A FGFR2 D650Y FGFR2 N652S FGFR2 K659Q cholangiocarcinoma predicted - resistant Infigratinib Case Reports/Case Series Actionable In a clinical case study, a patient with cholangiocarcinoma harboring an FGFR2-WAC fusion experienced disease progression after 5.6 months of treatment with Truseltiq (infigratinib) and was found to have acquired additional FGFR2 mutations, M537I, M538L, N549H, N549T, N549K, L550F, V564F, V564I, E565A, D650Y, N652S, K659Q (PMID: 34250419). 34250419
FGFR2 - KIAA1217 FGFR2 N549D FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 V564I FGFR2 V564L FGFR2 E565A FGFR2 L617F FGFR2 L617V FGFR2 K659M FGFR2 Q746L cholangiocarcinoma predicted - resistant Infigratinib Case Reports/Case Series Actionable In a clinical case study, a patient with cholangiocarcinoma harboring an FGFR2-KIAA1217 fusion experienced disease progression after 10.6 months of treatment with Truseltiq (infigratinib) and was found to have acquired additional FGFR2 mutations, N549K, N549D, N549H, V564F, V564I, V564L, E565A, L617V, L617F, K659M, Q746L (PMID: 34250419). 34250419
FGFR2 - ZMYM4 FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 E565A FGFR2 K659M cholangiocarcinoma predicted - resistant Infigratinib Case Reports/Case Series Actionable In a clinical case study, FGFR2 mutations E565A, K659M, N549H, N549K and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-ZMYM4 fusion after the patient progressed while on Truseltiq (infigratinib) treatment (PMID: 28034880). 28034880
FGFR2 K310R FGFR2 N549K endometrial carcinoma no benefit RO4987655 Preclinical - Cell culture Actionable In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO4987655 in culture (PMID: 26438159). 26438159
FGFR2 K310R FGFR2 N549K endometrial cancer predicted - sensitive Futibatinib Preclinical - Cell culture Actionable In a preclinical study, Futibatinib (TAS-120) treatment led to inhibition of cell proliferation in an endometrial cancer cell line harboring FGFR2 K310R and FGFR2 N549K in culture (PMID: 32973082). 32973082
FGFR2 K310R FGFR2 N549K endometrial carcinoma no benefit Selumetinib Preclinical - Cell culture Actionable In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159). 26438159
FGFR2 K310R FGFR2 N549K endometrial cancer sensitive Debio 1347 Preclinical Actionable In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 K310R and FGFR2 N549K mutations in culture (PMID: 25169980). 25169980
FGFR2 K310R FGFR2 N549K endometrial carcinoma sensitive FIIN-1 Preclinical Actionable In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K and FGFR2 K310R mutations in culture (PMID: 20338520). 20338520
FGFR2 K310R FGFR2 N549K endometrial carcinoma no benefit RO5126766 Preclinical - Cell culture Actionable In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO5126766 in culture (PMID: 26438159). 26438159
FGFR2 - CCDC170 FGFR2 N549K FGFR2 K641R cholangiocarcinoma predicted - resistant Pemigatinib Case Reports/Case Series Actionable In a Phase II trial (FIGHT-202), a cholangiocarcinoma patient harboring FGFR2-CCDC170 experienced disease progression after 6.9 months of treatment with Pemazyre (pemigatinib), and was found to have acquired FGFR2 N549K and FGFR2 K641R (PMID: 33218975; NCT02924376). 33218975
FGFR2 - NRBF2 FGFR2 N549K cholangiocarcinoma predicted - resistant Pemigatinib Case Reports/Case Series Actionable In a Phase II trial (FIGHT-202), a cholangiocarcinoma patient harboring FGFR2-NRBF2 experienced disease progression after 13.1 months of treatment with Pemazyre (pemigatinib), and was found to have acquired FGFR2 N549K (PMID: 33218975; NCT02924376). 33218975
FGFR2 - CCDC6 FGFR2 N549D FGFR2 N549K FGFR2 V564I cholangiocarcinoma predicted - resistant Pemigatinib Case Reports/Case Series Actionable In a Phase I trial (FIGHT-101), a cholangiocarcinoma patient harboring FGFR2-CCDC6 experienced disease progression after initially responding to Pemazyre (pemigatinib), and was found to have acquired FGFR2 N549K, FGFR2 N549D, and FGFR2 V564I (PMID: 35176457; NCT02393248). 35176457
FGFR2 - NRAP FGFR2 N549K FGFR2 V564L cholangiocarcinoma predicted - resistant Infigratinib Case Reports/Case Series Actionable In a clinical case study, a patient with cholangiocarcinoma harboring an FGFR2-NRAP fusion experienced disease progression after seven months of treatment with Truseltiq (infigratinib) and was found to have acquired additional FGFR2 mutations, N549K and V564L (PMID: 34250419). 34250419
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries